Meningococcal vaccine | Primary dose(s) | Booster dose(s) |
MenACWY (for those age 11 through 21 years)* | MenACWY (any licensed vaccine):
| MenACWY (any licensed vaccine):
|
MenB (for those age 16 through 23 years based on shared decision-making)Δ | Preferred age: 16 through 18 years Either:
| Not routinely recommended unless the person becomes at risk (eg, exposed during an outbreak, occupational risk). |
ACIP: Advisory Committee on Immunization Practices; MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenB: serogroup B meningococcal vaccine.
* Although the ACIP recommends routine MenACWY vaccination only for adolescents age 11 through 18 years, MenACWY may be given to persons age 19 through 21 years who have not received a dose.
¶ For unvaccinated adolescents and young adults with an underlying condition for which a 2-dose primary series of MenACWY vaccination is recommended, the second dose should be given as soon after the 8-week minimum interval as possible.
Δ Given the seriousness of meningococcal disease and efficacy and safety of available formulations, we suggest MenB for persons age 16 through 23 years.Do you want to add Medilib to your home screen?